Clinical Trials Collection
The AACR editors are proud to present this selection of impactful journal articles focusing on clinical trials, published from across the AACR journal portfolio.
Clinical trial of 2phenethyl isothiocyanate as an inhibitor of metabolic activation of a tobaccospecific lung carcinogen in cigarette smokers.
Hecht SS, Yuan JM, Stepanov I, Murphy SE, Wang R, Allen SS, et al. Cancer Prevention Research 2016; DOI:10.1158/19406207.CAPR150380. [Published OnlineFirst March 7, 2016].
A randomized, placebocontrolled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients.
Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, GuerrieriGonzaga A, et al. Cancer Prevention Research 2016; DOI:10.1158/19406207.CAPR150311. [Published OnlineFirst February 29, 2016].
Effect of weight loss with or without exercise on inflammatory markers and adipokines in postmenopausal women: the SHAPE2 trial, a randomized controlled trial.
van Gemert WA, May AM, Schuit AJ, Oosterhof BYM, Peeters PH, Monninkhof EM. Cancer Epidemiology, Biomarkers & Prevention 2016; DOI:10.1158/10559965.EPI151065. [Published OnlineFirst February 16, 2016].
Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer.
Hill EJ, Roberts C, Franklin JM, Enescu M, West N, Macgregor TP, et al. Clinical Cancer Research 2016; DOI:10.1158/10780432.CCR151489. [Published OnlineFirst February 9, 2016].
A multiinstitution phase 1 trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML).
Padron E, Dezern A, AndradeCampos M, Vaddi K, Scherle P, Zhang Q, et al. Clinical Cancer Research 2016; DOI:10.1158/10780432.CCR152781. [Published OnlineFirst February 8, 2016].
Phase I study of random healthy donor–derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors.
Yang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, et al. Cancer Immunology Research 2016;4:215–24.
Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial.
Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:463–9.
Exploring the feasibility of a broadreach physical activity behavior change intervention for women receiving chemotherapy for breast cancer: a randomized trial.
Vallance JK, Friedenreich CM, Lavallee CM, CulosReed N, Mackey JR, Walley B, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:391–8.
A firstinhuman phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer.
Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, et al. Clinical Cancer Research 2016;22:1095–102.
Short peptide vaccine induces CD4+ T helper cells in patients with different solid cancers.
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, et al. Cancer Immunology Research 2016;4:18–25.
Vaccination with LAG3Ig (IMP321) and peptides induces specific CD4 and CD8 Tcell responses in metastatic melanoma patients—report of a phase I/IIa clinical trial.
Legat A, Hajjami ME, Baumgaertner P, Cagnon L, Maillard SA, Geldhof C, et al. Clinical Cancer Research 2016;22:1330–40.
Phase I trial of a yeastbased therapeutic cancer vaccine (GI6301) targeting the transcription factor brachyury.
Heery CR, Singh BH, Rauckhorst M, Marté JL, Donahue RN, Grenga I, et al. Cancer Immunology Research 2015;3:1248–56.
Safety and activity of the firstinclass Sym004 antiEGFR antibody mixture in patients with refractory colorectal cancer.
Dienstmann R, Patnaik A, GarciaCarbonero R, Cervantes A, Benavent M, Roselló S, et al. Cancer Discovery 2015;5:598–609.
Prospective blinded study of BRAFV600E mutation detection in cellfree DNA of patients with systemic histiocytic disorders.
Hyman DM, Diamond EL, Vibat CRT, Hassaine L, Poole JC, Patel M, et al. Cancer Discovery 2015;5:64–71.